File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A synopsis of current care of thalassaemia major patients in Hong Kong

TitleA synopsis of current care of thalassaemia major patients in Hong Kong
Authors
KeywordsBeta-Thalassemia
Blood transfusion
Chelation therapy
Hemosiderosis
Iron chelating agents
Issue Date2011
PublisherHong Kong Academy of Medicine Press. The Journal's web site is located at http://www.hkmj.org.hk
Citation
Hong Kong Medical Journal, 2011, v. 17 n. 4, p. 261-266 How to Cite?
AbstractOBJECTIVE: To provide a synopsis of current thalassaemia major patient care in Hong Kong. DESIGN: Retrospective study. SETTING: All haematology units of the Hospital Authority in Hong Kong. PATIENTS: All patients with thalassaemia major with regular transfusion. RESULTS: To date, there were 363 thalassaemia major patients under the care of the Hospital Authority. Prenatal diagnosis has helped to reduce the number of indigenous new cases, but in recent years immigrant cases are appearing. The patients have a mean age of 23 (range, 1-52) years, and 78% of them are adults. In 2009, they received 18 782 units of blood. This accounted for 9.5% of all blood consumption from the Hong Kong Red Cross. In the past, cardiac iron overload was the major cause of death (65%) and few patients survived beyond the age of 45 years. The availability of cardiac iron assessment by magnetic resonance imaging (T2 MRI) to direct the use of oral deferiprone chelation has reduced the prevalence of heart failure and cardiac haemosiderosis, which should reduce mortality and improve life expectancy. CONCLUSION: The future for thalassaemia care in Hong Kong is bright. With better transfusion and chelation, it should be possible to avoid growth and endocrine deficiencies in younger patients.
Persistent Identifierhttp://hdl.handle.net/10722/152728
ISSN
2023 Impact Factor: 3.1
2023 SCImago Journal Rankings: 0.261

 

DC FieldValueLanguage
dc.contributor.authorAu, WYen_US
dc.contributor.authorLee, Ven_US
dc.contributor.authorLau, CWen_US
dc.contributor.authorYau, Jen_US
dc.contributor.authorChan, Den_US
dc.contributor.authorChan, EYTen_US
dc.contributor.authorCheung, WWWen_US
dc.contributor.authorHa, SYen_US
dc.contributor.authorKho, Ben_US
dc.contributor.authorLee, CYen_US
dc.contributor.authorLi, RCHen_US
dc.contributor.authorLi, CKen_US
dc.contributor.authorLin, SYen_US
dc.contributor.authorLing, ASCen_US
dc.contributor.authorMak, Ven_US
dc.contributor.authorSun, Len_US
dc.contributor.authorWong, KHFen_US
dc.contributor.authorWong, Ren_US
dc.contributor.authorYuen, HLen_US
dc.date.accessioned2012-07-16T09:47:22Z-
dc.date.available2012-07-16T09:47:22Z-
dc.date.issued2011en_US
dc.identifier.citationHong Kong Medical Journal, 2011, v. 17 n. 4, p. 261-266en_US
dc.identifier.issn1024-2708-
dc.identifier.urihttp://hdl.handle.net/10722/152728-
dc.description.abstractOBJECTIVE: To provide a synopsis of current thalassaemia major patient care in Hong Kong. DESIGN: Retrospective study. SETTING: All haematology units of the Hospital Authority in Hong Kong. PATIENTS: All patients with thalassaemia major with regular transfusion. RESULTS: To date, there were 363 thalassaemia major patients under the care of the Hospital Authority. Prenatal diagnosis has helped to reduce the number of indigenous new cases, but in recent years immigrant cases are appearing. The patients have a mean age of 23 (range, 1-52) years, and 78% of them are adults. In 2009, they received 18 782 units of blood. This accounted for 9.5% of all blood consumption from the Hong Kong Red Cross. In the past, cardiac iron overload was the major cause of death (65%) and few patients survived beyond the age of 45 years. The availability of cardiac iron assessment by magnetic resonance imaging (T2 MRI) to direct the use of oral deferiprone chelation has reduced the prevalence of heart failure and cardiac haemosiderosis, which should reduce mortality and improve life expectancy. CONCLUSION: The future for thalassaemia care in Hong Kong is bright. With better transfusion and chelation, it should be possible to avoid growth and endocrine deficiencies in younger patients.-
dc.languageengen_US
dc.publisherHong Kong Academy of Medicine Press. The Journal's web site is located at http://www.hkmj.org.hk-
dc.relation.ispartofHong Kong Medical Journalen_US
dc.rightsHong Kong Medical Journal. Copyright © Hong Kong Academy of Medicine Press.-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectBeta-Thalassemia-
dc.subjectBlood transfusion-
dc.subjectChelation therapy-
dc.subjectHemosiderosis-
dc.subjectIron chelating agents-
dc.subject.meshErythrocyte Transfusion-
dc.subject.meshIron Overload - etiology-
dc.subject.meshOsteoporosis - etiology-
dc.subject.meshRetrospective Studies-
dc.subject.meshThalassemia - complications - mortality - therapy-
dc.titleA synopsis of current care of thalassaemia major patients in Hong Kongen_US
dc.typeArticleen_US
dc.identifier.emailAu, WY: auwing@hkucc.hku.hk, auwing@hotmail.comen_US
dc.identifier.emailHa, SY: syha@hku.hken_US
dc.description.naturepublished_or_final_version-
dc.identifier.pmid21813892-
dc.identifier.scopuseid_2-s2.0-80052925400-
dc.identifier.hkuros200825en_US
dc.identifier.volume17en_US
dc.identifier.issue4en_US
dc.identifier.spage261en_US
dc.identifier.epage266en_US
dc.publisher.placeHong Kong-
dc.identifier.issnl1024-2708-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats